145 related articles for article (PubMed ID: 31740718)
1. Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression.
Kotecha S; Lebot MN; Sukkarn B; Ball G; Moseley PM; Chan SY; Green AR; Rakha E; Ellis IO; Martin SG; Storr SJ
Sci Rep; 2019 Nov; 9(1):16987. PubMed ID: 31740718
[TBL] [Abstract][Full Text] [Related]
2. PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression.
Saidy B; Kotecha S; Butler A; Rakha EA; Ellis IO; Green AR; Martin SG; Storr SJ
J Cell Mol Med; 2021 Jun; 25(11):5015-5024. PubMed ID: 33991172
[TBL] [Abstract][Full Text] [Related]
3. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
[TBL] [Abstract][Full Text] [Related]
4. Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer.
Saidy B; Rakha EA; Green AR; Ellis IO; Martin SG; Storr SJ
J Cell Mol Med; 2020 Jun; 24(11):6263-6271. PubMed ID: 32352232
[TBL] [Abstract][Full Text] [Related]
5. Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.
Avanes A; Lenz G; Momand J
Biochem Pharmacol; 2019 Feb; 160():71-79. PubMed ID: 30552871
[TBL] [Abstract][Full Text] [Related]
6. Dopamine and cAMP-regulated phosphoprotein 32kDa (DARPP-32), protein phosphatase-1 and cyclin-dependent kinase 5 expression in ovarian cancer.
Martin SG; Zhang S; Yang S; Saidy B; Deen S; Storr SJ
J Cell Mol Med; 2020 Aug; 24(16):9165-9175. PubMed ID: 32588513
[TBL] [Abstract][Full Text] [Related]
7. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
[No Abstract] [Full Text] [Related]
8. DARPP-32: from neurotransmission to cancer.
Belkhiri A; Zhu S; El-Rifai W
Oncotarget; 2016 Apr; 7(14):17631-40. PubMed ID: 26872373
[TBL] [Abstract][Full Text] [Related]
9. t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit.
Theile D; Geng S; Denny EC; Momand J; Kane SE
Cell Signal; 2017 Dec; 40():53-61. PubMed ID: 28867659
[TBL] [Abstract][Full Text] [Related]
10. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
Christenson JL; Denny EC; Kane SE
Oncotarget; 2015 Oct; 6(32):33134-45. PubMed ID: 26430732
[TBL] [Abstract][Full Text] [Related]
11. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
12. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer.
Vangamudi B; Peng DF; Cai Q; El-Rifai W; Zheng W; Belkhiri A
Mol Cancer; 2010 Sep; 9():240. PubMed ID: 20836878
[TBL] [Abstract][Full Text] [Related]
13. Darpp-32 and t-Darpp are differentially expressed in normal and malignant mouse mammary tissue.
Christenson JL; Kane SE
Mol Cancer; 2014 Aug; 13():192. PubMed ID: 25128420
[TBL] [Abstract][Full Text] [Related]
14. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.
Murad R; Avanes A; Ma X; Geng S; Mortazavi A; Momand J
Gene; 2021 Oct; 799():145808. PubMed ID: 34224831
[TBL] [Abstract][Full Text] [Related]
16. t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells.
Denny EC; Kane SE
PLoS One; 2015; 10(6):e0132267. PubMed ID: 26121470
[TBL] [Abstract][Full Text] [Related]
17. DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Bon G; Krasniqi E; Porru M; D'Ambrosio L; Scalera S; Maugeri-Saccà M; Di Lisa FS; Filomeno L; Arcuri T; Botticelli A; Santini D; Fabbri MA; D'Auria G; Pulito C; Blandino G; Marchiò C; Barba M; Ciliberto G; Vici P; Pizzuti L
Neoplasia; 2023 Nov; 45():100937. PubMed ID: 37769528
[TBL] [Abstract][Full Text] [Related]
18. An association study between PPP1R1B gene and schizophrenia in the Chinese population.
Hu JX; Yu L; Shi YY; Zhao XZ; Meng JW; He G; Xu YF; Feng GY; He L
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1303-6. PubMed ID: 17618027
[TBL] [Abstract][Full Text] [Related]
19. Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways.
Saidy B; Vasan R; Durant R; Greener MR; Immanuel A; Green AR; Rakha E; Ellis I; Ball G; Martin SG; Storr SJ
Sci Rep; 2023 Nov; 13(1):21163. PubMed ID: 38036593
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein in common adenocarcinomas.
Beckler A; Moskaluk CA; Zaika A; Hampton GM; Powell SM; Frierson HF; El-Rifai W
Cancer; 2003 Oct; 98(7):1547-51. PubMed ID: 14508844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
